Http://www.ingentaconnect.com/content/mksg/acp/2001/00000104/00

IngentaConnect Post-dexamethasone cortisol correlateswith severity of depression.
during carbamazepine treatment in women Authors: Osuch, Elizabeth A.1; Cora-Locatelli,
Gabriela2; Frye, Mark A.3; Huggins, Teresa2; Kimbrell,
Timothy A.4; Ketter, Terence A.5; Callahan, Ann M.2; Post,
Robert M.2
Source: Acta Psychiatrica Scandinavica, Volume 104, Number
5, November 2001 , pp. 397-401(5)
Publisher: Blackwell Publishing
< previous article | next article > | view table of Key: - Free Content - New Content - Subscribed
Content - Free Trial Content
Abstract:
Objective: Previous studies show a state-dependent
relationship between depression and post-dexamethasone
suppression test (DST) cortisol level, as well as differences in

Method: In this study, 74 research in-patients with affective
disorders were given the DST on placebo and in a subgroup
following treatment with carbamazepine. Depression was evaluated twice daily with the Bunney-Hamburg (BH) rating scale. Data were examined for the total subject population, by gender and by menopausal status in women.
Results: A robust positive correlation was observed between
depression severity and post-DST cortisol in pre- and
postmenopausal females, but not in males. This relationship persisted in women when restudied on a stable dose of http://www.ingentaconnect.com/content/mksg/acp/2001/00000104/00000005/art00014;jse.
IngentaConnect Post-dexamethasone cortisol correlateswith severity of depression.

Conclusion: The pathophysiological implications of this
selective positive relationship between severity of depression
and post-DST cortisol in women, but not men, should be
Keywords: dexamethasone; cortisol; depression; gender;
menopause; carbamazepine
Document Type: Research article
Affiliations: 1: Uniformed Services University of the Health
Sciences, Bethesda, MD, 2: Biological Psychiatry Branch,
National Institute of Mental Health (NIMH), National Institutes
of Health (NIH), Bethesda, MD, 3: UCLA School of Medicine,
Los Angeles, CA, 4: North Little Rock VA Medical Center,
North Little Rock, Arkansas and 5: Stanford University School
of Medicine, Stanford, CA, USA
<p class="rust">The full text article is temporarily unavailable.</p> <p>We apologise for the inconvenience. Please try again later.</p> < previous article | next article > | view table of Key: - Free Content - New Content - Subscribed
Website 2008 Ingenta. Article copyright remains with the publisher, societor author(s) as specified within the article. Terms and Conditions Privacy Policy Information for advert http://www.ingentaconnect.com/content/mksg/acp/2001/00000104/00000005/art00014;jse.

Source: http://www.floridaneuroscience.com/postdst.pdf

nijophasr.com

Nigerian Journal of Pharmaceutical and Applied Science Research, 2012, 1(2): 91-97 QUALITY ASSESSMENT OF SOME BRANDS OF PIROXICAM CAPSULES Igboasoiyi A.C.*, Eseyin O.A., Oladimeji H.O., and Akpan R.J. Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmacy, University of Uyo . *Author for correspondence; E-mail: [email protected] Phone: +23480332

Technical report for ceretrophin clinical study (06-29)

Technical Report for Ceretrophin™ Clinical Study* Professor Con Stough, Ph.D., Brain Sciences Institute, Swinburne University, Melbourne Victoria, AUSTRALIA The study investigators were: Prof Con Stough, Ph.D. (Principle investigator) Christina Kure (clinical trials coordinator) Jo Tarasuik (Research Assistant) Luke Downey (Research Assistant) Jenny Lloyd (Research Nurse) * Ceretro

Copyright © 2009-2018 Drugs Today